| 1 |
Abdalhabib EK, Jackson DE, Alzahrani B, Elfaki E, Hamza A, Mohamed Elasbali A, Alanazi F, Algarni A, Khider Ibrahim I, Saboor M. Age- and Gender-Independent Association of XRCC1 Arg399Gln Polymorphism with Chronic Myeloid Leukemia. Int J Gen Med 2021;14:8231-6. [PMID: 34815696 DOI: 10.2147/IJGM.S340283] [Reference Citation Analysis]
|
| 2 |
Rahimian E, Amini A, Alikarami F, Pezeshki SMS, Saki N, Safa M. DNA repair pathways as guardians of the genome: Therapeutic potential and possible prognostic role in hematologic neoplasms. DNA Repair (Amst) 2020;96:102951. [PMID: 32971475 DOI: 10.1016/j.dnarep.2020.102951] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 3 |
Mahmoud AA, Hassan MH, Ghweil AA, Abdelrahman A, Mohammad AN, Ameen HH. Urinary 8-hydroxydeoxyguanosine in relation to XRCC1 rs25487 G/A (Arg399Gln) and OGG1 rs1052133 C/G (Ser326Cys) DNA repair genes polymorphisms in patients with chronic hepatitis C and related hepatocellular carcinoma. Cancer Manag Res 2019;11:5343-51. [PMID: 31354343 DOI: 10.2147/CMAR.S209112] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 4 |
Wang F, Zhao Q, He HR, Zhai YJ, Lu J, Hu HB, Zhou JS, Yang YH, Li YJ. The association between XRCC1 Arg399Gln polymorphism and risk of leukemia in different populations: a meta-analysis of case-control studies. Onco Targets Ther 2015;8:3277-87. [PMID: 26609240 DOI: 10.2147/OTT.S92752] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 5 |
Salimizand H, Amini S, Abdi M, Ghaderi B, Azadi N. Concurrent effects of ABCB1 C3435T, ABCG2 C421A, and XRCC1 Arg194Trp genetic polymorphisms with risk of cancer, clinical output, and response to treatment with imatinib mesylate in patients with chronic myeloid leukemia. Tumor Biol 2016;37:791-8. [DOI: 10.1007/s13277-015-3874-4] [Cited by in Crossref: 20] [Cited by in F6Publishing: 27] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 6 |
Mutlu P, Elçi MP, Yıldırım M, Nevruz O, Çetin AT, Avcu F. Identification of XRCC1 Arg399Gln and XRCC3 Thr241Met Polymorphisms in a Turkish Population and Their Association with the Risk of Chronic Lymphocytic Leukemia. Indian J Hematol Blood Transfus 2015;31:332-8. [PMID: 26085717 DOI: 10.1007/s12288-014-0482-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 7 |
Du L, Liu Y, Xue P, Song C, Shen J, He Q, Peng Y, Tong X, Tang L, Zhang Y. The Arg399Gln polymorphism in the XRCC1 gene is associated with increased risk of hematological malignancies. Tumor Biol 2015;36:4545-54. [DOI: 10.1007/s13277-015-3099-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 8 |
Feng YZ, Liu YL, He XF, Wei W, Shen XL, Xie DL. Association between the XRCC1 Arg194Trp polymorphism and risk of cancer: evidence from 201 case-control studies. Tumour Biol 2014;35:10677-97. [PMID: 25064613 DOI: 10.1007/s13277-014-2326-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 9 |
Bănescu C, Trifa AP, Demian S, Benedek Lazar E, Dima D, Duicu C, Dobreanu M. Polymorphism of XRCC1, XRCC3, and XPD genes and risk of chronic myeloid leukemia. Biomed Res Int 2014;2014:213790. [PMID: 24955348 DOI: 10.1155/2014/213790] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 10 |
Tang L, Xiong T, Jia Q, He Q, Tong X, Peng Y, Shen J, Yang J, Zhang Y. Study on the association between the Arg194Trp polymorphism in the XRCC1 gene and the risk of hematological malignancies. Tumor Biol 2014;35:3009-16. [DOI: 10.1007/s13277-013-1388-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 11 |
Qi Y, Cui L, Song Y, Li N. XRCC1 Arg399Gln genetic polymorphism and the risk of hepatocellular carcinoma: a meta-analysis. Mol Biol Rep 2014;41:879-87. [PMID: 24390232 DOI: 10.1007/s11033-013-2929-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 12 |
Zhang H, Liu H, Jiang G. Genetic polymorphisms of XRCC1 and leukemia risk: a meta-analysis of 19 case-control studies. PLoS One 2013;8:e80687. [PMID: 24363792 DOI: 10.1371/journal.pone.0080687] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 13 |
Huang Y, Xie D, Tang N, Wang J, Zeng X, Zhao P, He L. XRCC1 Arg399Gln variation and leukemia susceptibility: evidence from 2,647 cases and 5,518 controls. Tumour Biol 2014;35:799-808. [PMID: 23990457 DOI: 10.1007/s13277-013-1110-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 14 |
Sava GP, Speedy HE, Houlston RS. Candidate gene association studies and risk of chronic lymphocytic leukemia: a systematic review and meta-analysis. Leuk Lymphoma 2014;55:160-7. [PMID: 23647060 DOI: 10.3109/10428194.2013.800197] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 15 |
Annamaneni S, Gorre M, Kagita S, Addepalli K, Digumarti RR, Satti V, Battini MR. Association of XRCC1 gene polymorphisms with chronic myeloid leukemia in the population of Andhra Pradesh, India. Hematology 2013;18:163-8. [PMID: 23320983 DOI: 10.1179/1607845412Y.0000000040] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
|
